BostonGene Named Platinum Winner for AI Research Innovation at 2025 Pinnacle Awards
BostonGene, a leader in AI-powered solutions for drug discovery and development, has won Platinum in the AI Research Innovation category at the 2025 Pinnacle Awards. This recognition underscores BostonGene’s pivotal role in transforming multiomic data into actionable insights that drive smarter trial design, enable patient stratification and accelerate development timeliness--helping bring therapies to patients faster.
“We’re proud to receive this award, which highlights the impact of our platform in advancing therapeutic development,” said Alexander Bagaev, PhD, Chief Product Officer at BostonGene. “By integrating AI, multiomic profiling and real-world evidence, we enable drug developers to make smarter decisions—identifying responder populations, de-risking pipelines and shortening trial timelines. The result is a faster path to life-changing treatments for patients.”
AI-Powered Innovation Driving Therapeutic Success
BostonGene’s platform integrates genomic, transcriptomic, immune and spatial profiling—including whole exome and transcriptome sequencing, liquid biopsy, flow cytometry and spatial proteomics—delivering a comprehensive, multidimensional view of disease biology.
With this integrated view, the platform enables:
Discovering predictive biomarkers to guide precision trial design
Improving patient stratification to increase response rates
Assessing adverse event risk to strengthen safety
Optimizing trial endpoints and inclusion criteria to accelerate development
Breaking Through Traditional Limitations
Unlike conventional approaches that rely on static, single-gene markers, BostonGene’s proprietary AI models—trained on large-scale, real-world datasets—capture the full complexity of the tumor and immune microenvironment.
These models enable:
Predicting treatment response with greater accuracy
Identifying resistance mechanisms earlier
Reducing late-stage clinical trial failures
By providing decision-ready evidence from discovery through pivotal trials, BostonGene empowers drug developers to optimize trial design, prioritize assets with confidence, minimize R&D risk and accelerate commercialization.
The Pinnacle Awards celebrate innovation and excellence in technology across industries. Judged by a panel of industry experts, the program honors organizations delivering measurable impact through breakthrough solutions that set new standards in their fields.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
